The cross-link below provides recent reported finds entitled "Trastuzumab [Herceptin] and Vinorelbine [Navelbine] as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes Analysis of Serum Tumor Markers as Predictive Factors and Cardiac Surveillance Algorithm."

These findings are reported in the August 1 2003 edition of the Journal of Clinical Oncology (Vol 21 Issue 15 pp. 2889-2895). The JCO is a publication of the American Society of Clinical Oncology (ASCO).